Skip to main content
. 2017 Oct 24;8(1):2045893217741429. doi: 10.1177/2045893217741429

Fig. 11.

Fig. 11.

Dual ETA/ETB and selective ETB receptor antagonism increases the angiogenic potential of PAECs isolated from the distal pulmonary artery of patients with PAH. Treatments with dual ETA/ETB receptor antagonist (macitentan, 10–6 M) or selective ETB receptor antagonist (BQ788, 10–6 M) improved the angiogenic capacity of PAH–PAECs as evaluated by Matrigel assays. Macitentan treatment significantly reduced the number of isolated segments while it improved the number of nodes formation, which reflects an increased capacity of PAH–PAECs to do tube formation. ETB receptor antagonism also significantly increased the number of nodes formation in PAH–PAECs when compared to vehicle-treated cells. Four pictures/well were taken and automatic quantification of tubing formation was performed with the Image J Angiogenesis Analyzer (n = 3 cell lines/treatment, passage 2–5). *P < 0.05; **P < 0.01 (n = 3). Scale bars: 500 µm in upper panel; 100 µm in lower panel.